{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:51:24Z","timestamp":1740153084203,"version":"3.37.3"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Our objective was to assess the effectiveness of conventional and targeted disease-modifying antirheumatic drugs (cDMARDs and tDMARDs, respectively) in treating enthesitis in psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with active enthesitis, defined as \u2265 1 tender entheses (of the 29 enthesis sites included in the Spondyloarthritis Research Consortium of Canada Enthesitis Index, the Leeds Enthesitis Index, and the Maastricht Ankylosing Spondylitis Enthesitis Score), who were enrolled in a large PsA cohort were included. Medications at baseline were classified into 3 mutually exclusive categories: (1) no treatment or nonsteroidal antiinflammatory drugs (NSAIDs) only; (2) cDMARDs \u00b1 NSAIDs; and (3) tDMARDs \u00b1 cDMARDs\/NSAIDs. Complete resolution of enthesitis (no tender enthesis) at 12 months was the primary outcome. Logistic regression models were developed to determine the association between medication category and enthesitis resolution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 1270 patients studied, 628 (49.44%) had enthesitis. Of these, 526 patients (51.71% males; mean [SD] age 49.02 [13.12] years; mean enthesitis score 2.13 [2.16]; median enthesitis score 2 [IQR 1-2]), with adequate follow-up were analyzed. Complete resolution of enthesitis was noted in 453 (86.12%) patients, within a mean period of 8.73 (3.48) months from baseline. In the regression analysis, though not significant, DMARDs (categories II and III) had higher odds ratios (ORs) compared to category 1 for resolution of enthesitis. Enthesitis resolution was associated with lower joint activity (OR 0.97, 95% CI 0.95-0.99;<jats:italic>P<\/jats:italic>= 0.01) and male sex (OR 1.66, 95% CI 0.97-2.84;<jats:italic>P<\/jats:italic>= 0.06).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Resolution of enthesitis was observed in 86% of patients in an observational setting regardless of the medication used. Future effectiveness studies may warrant evaluation of enthesitis using advanced imaging.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.211231","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:20:22Z","timestamp":1654086022000},"page":"1020-1025","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-2042","authenticated-orcid":false,"given":"Ashish J.","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2022090609450700000_49.9.1020.1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022090609450700000_49.9.1020.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2022090609450700000_49.9.1020.3","doi-asserted-by":"crossref","first-page":"108390","DOI":"10.1016\/j.clim.2020.108390","article-title":"Challenges in the clinical diagnosis of psoriatic arthritis","volume":"214","author":"Rida","year":"2020","journal-title":"Clin Immunol"},{"key":"2022090609450700000_49.9.1020.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"2022090609450700000_49.9.1020.5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022090609450700000_49.9.1020.6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022090609450700000_49.9.1020.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2022090609450700000_49.9.1020.8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2022090609450700000_49.9.1020.9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-017-1399-5","article-title":"The association between sonographic enthesitis and radiographic damage in psoriatic arthritis","volume":"19","author":"Polachek","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022090609450700000_49.9.1020.10","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1093\/rheumatology\/keaa042","article-title":"Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management","volume":"59","author":"Mease","year":"2020","journal-title":"Rheumatology"},{"key":"2022090609450700000_49.9.1020.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2022090609450700000_49.9.1020.12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheum"},{"key":"2022090609450700000_49.9.1020.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2022090609450700000_49.9.1020.14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022090609450700000_49.9.1020.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217163"},{"key":"2022090609450700000_49.9.1020.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq262"},{"key":"2022090609450700000_49.9.1020.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.23104"},{"key":"2022090609450700000_49.9.1020.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160387"},{"key":"2022090609450700000_49.9.1020.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110165"},{"key":"2022090609450700000_49.9.1020.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"2022090609450700000_49.9.1020.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"2022090609450700000_49.9.1020.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"2022090609450700000_49.9.1020.23","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology"},{"key":"2022090609450700000_49.9.1020.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121145"},{"key":"2022090609450700000_49.9.1020.25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2022090609450700000_49.9.1020.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180797"},{"key":"2022090609450700000_49.9.1020.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.463"},{"key":"2022090609450700000_49.9.1020.28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheum"},{"key":"2022090609450700000_49.9.1020.29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/rheumatology\/key369","article-title":"Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis","volume":"58","author":"Appani","year":"2019","journal-title":"Rheumatology"},{"key":"2022090609450700000_49.9.1020.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150614"},{"key":"2022090609450700000_49.9.1020.31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000486"},{"key":"2022090609450700000_49.9.1020.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200084"},{"key":"2022090609450700000_49.9.1020.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171411"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.211231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T14:20:32Z","timestamp":1700662832000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.211231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.3899\/jrheum.211231"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.211231","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}